4-1bbζ cd19-her2tg
Vaccineexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 13, 2020 (NCT04483778)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma · Phase 1
- Desmoplastic Small Round Cell Tumor · Phase 1
- Hepatoblastoma · Phase 1
- Melanoma · Phase 1
- Neoplasms · Phase 1
- Neoplasms, Germ Cell and Embryonal · Phase 1
- Neuroblastoma · Phase 1
- Neurofibrosarcoma · Phase 1
- Osteosarcoma · Phase 1
- Retinoblastoma · Phase 1
- Rhabdoid Tumor · Phase 1
- Rhabdomyosarcoma · Phase 1
- Sarcoma · Phase 1
- Sarcoma, Clear Cell · Phase 1
- Sarcoma, Ewing · Phase 1
- Sarcoma, Synovial · Phase 1
- Wilms Tumor · Phase 1
Mechanism of action
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04483778 | Phase 1 | Jul 13, 2020 | University of Washington |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2020 |
1 organizations
Page 1 / 1